Reuters logo
BRIEF-U.S. FDA grants priority review status to Ultragenyx metabolic disorder drug
May 23, 2017 / 12:52 PM / 4 months ago

BRIEF-U.S. FDA grants priority review status to Ultragenyx metabolic disorder drug

May 23 (Reuters) - Ultragenyx Pharmaceutical Inc-

* Ultragenyx announces recombinant human beta-glucuronidase biologics license application and marketing authorization application filed and accepted for review; FDA grants priority review status

* Ultragenyx Pharmaceutical Inc - prescription drug user fee act (pdufa) goal date for a decision is november 16, 2017

* Ultragenyx Pharmaceutical Inc - opinion from committee for medicinal products for human use (chmp) is expected in first half of 2018 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below